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Introduction: Vasculopathy, inflammatory fibrosis and functional autoantibodies (Abs) are major manifestations of
systemic sclerosis (SSc). Abs directed against the angiotensin II type 1 receptor (AT1R) and endothelin-1 type A
receptor (ETAR) are associated with characteristic disease features including vascular, inflammatory, and fibrotic
complications indicating their role in SSc pathogenesis. Therefore, the impact of anti-AT1R and anti-ETAR Abs on
initiation of inflammation and fibrosis was analyzed.
Methods: Anti-AT1R and anti-ETAR Ab-positive immunoglobulin G (IgG) from SSc patients (SSc-IgG) was used for
experiments. Healthy donor IgG served as a normal control, and AT1R and ETAR activation was inhibited by
antagonists. Protein expression was measured with ELISA, mRNA expression with real time-PCR, endothelial repair
with a scratch assay, and collagen expression with immunocytochemistry. Transendothelial neutrophil migration
was measured with a culture insert system, and neutrophil ROS activation with immunofluorescence. Neutrophils in
bronchoalveolar lavage fluids (BALFs) were analyzed microscopically after passive transfer of SSc-IgG or NC-IgG into
naïve C57BL/6J mice. KC plasma levels were quantified by a suspension array system. Histologic analyses were
performed by using light microscopy.
Results: Anti-AT1R and anti-ETAR Ab-positive SSc-IgG induced activation of human microvascular endothelial cells
(HMEC-1). Elevated protein and mRNA levels of the proinflammatory chemokine interleukin-8 (IL-8, CXCL8) and
elevated mRNA levels of the vascular cell adhesion molecule-1 (VCAM-1) were induced in HMEC-1. Furthermore,
activation of HMEC-1 with SSc-IgG increased neutrophil migration through an endothelial cell layer and activation
of reactive oxygen species (ROS). SSc-IgG decreased HMEC-1 wound repair and induced type I collagen production
in healthy donor skin fibroblasts. Effects of migration, wound repair, and collagen expression were dependent on
the Ab-levels. Passive transfer of anti-AT1R and anti-ETAR Ab-positive SSc-IgG into naïve C57BL/6J mice increased
neutrophil BALF counts. In parallel, increased levels of the murine functional IL-8 homologue, chemokine KC, were
found in the plasma of SSc-IgG-treated mice as well as structural alterations of the lungs.
Conclusions: We conclude that angiotensin and endothelin-receptor activation via anti-AT1R and anti-ETAR Abs
mediate pathogenic effects, indicating their contribution to pathogenesis of SSc. Therefore, anti-AT1R and anti-ETAR
Abs could provide novel targets for therapeutic intervention in the treatment of SSc.* Correspondence: Gabriela.Riemekasten@charite.de
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Systemic sclerosis (SSc) is an autoimmune disorder with
severe clinical manifestations, high mortality, and limited
therapeutic options. Autoimmunity, vasculopathy, and fi-
brosis are hallmarks of the disease [1,2]. So far, mecha-
nisms by which these hallmarks may be linked together
are not well understood. Recent work from our group has
shown that anti-AT1R and anti-ETAR Abs are present in
SSc [3], and that elevated Ab levels in sera are correlated
with major disease manifestations, emphasizing their po-
tential role in SSc pathogenesis. It is well established that
microvascular damage, featuring endothelial cell dysfunc-
tion and perivascular infiltrates, is a key event in SSc
pathogenesis appearing early in the course of the disease
and preceding fibrosis [4-6]. Inflammation also is a crucial
event in SSc development and is reflected by abnormal
chemokine and cytokine levels in sera and BALF [7-9], as
well as by inflammatory infiltrates [2,4]. Of note are ele-
vated levels of IL-8, both in sera and in BALF [7,9,10].
Furthermore, the latter were connected to neutrophilic
alveolitis in SSc-related interstitial lung disease [7,11],
demonstrating a link between increased IL-8 levels and
neutrophil accumulation.
Progressive fibrosis is characterized by amplified pro-
duction of extracellular matrix (ECM) components includ-
ing increased collagen synthesis by fibroblasts. SSc skin
fibroblasts have been demonstrated to produce higher
amounts of collagen when compared with skin fibroblasts
from healthy donors [12,13]. Similarly, increased collagen
expression was found in an animal model of SSc [14].
Last, an increased activation of the angiotensin and
endothelin axis has been reported in SSc [15-17]. Ac-
cordingly, we reasoned that anti-AT1R and anti-ETAR
Abs could directly contribute to the initiation of inflam-
mation and fibrosis in vitro and in vivo by activation of
endothelial cells, fibroblasts, and neutrophils and thus
contribute to the key pathogenic manifestations of SSc.
The objective of this study was to analyze the impact of
functional anti-AT1R and anti-ETAR Abs on inflamma-




All reagents were purchased from Sigma Aldrich
(Germany), if not otherwise stated.
Ethical admission for patient sample collection and
performance of animal experiments
Serum was collected from venous blood after written in-
formed consent and local ethics committee approval
(EA1/013/705). Healthy donor skin was obtained by bi-
opsy after written informed consent and approval by Uni-
versity Hospital Charité ethics committee (EA1/168/06).C57BL/6J mice were obtained from Charles River (Sulz-
feld, Germany). Experiments were performed according to
institutional and federal guidelines (Landesamt für Ge-
sundheit und Soziales, Berlin, Germany).
Patients and healthy control donors
SSc patients with diffuse or limited SSc were classified
according to LeRoy and ACR criteria [1,18]. Patients
with established vasculopathy and/or fibrosis, including
pulmonary arterial hypertension (PAH), lung and skin fi-
brosis, were chosen for IgG isolation that subsequently
was used for experiments. Healthy control subjects
served as negative controls. Identical IgG processing was
used for SSc patients and healthy donors for serum col-
lection and IgG isolation. For functional assays, individ-
ual IgG samples were used that were isolated from one
serum sample as described later, followed by measure-
ment of anti-AT1R and anti-ETAR Abs levels of each
sample, as previously reported [3]. For animal experi-
ments, the same methods were used, except that IgG
was isolated from a pool of sera (from several patients
or healthy donors) to provide enough material. Detailed
patient and healthy donor control characteristics are
summarized in Table 1.
Isolation of IgG and detection of anti-AT1R and
anti-ETAR Abs
IgG was isolated by protein-G sepharose chromatography
in 20 mM phosphate buffer pH 7.0. IgG was eluted with
0.1 M glycine/HCl, pH 2.7, and pH was neutralized with 1
M Tris/HCl, pH 9.0. Eluted IgG was dialyzed against PBS,
and absorbance was measured at 280 nm (Emax, Molecu-
lar Devices, USA). Anti-AT1R and anti-ETAR Abs were
detected in purified IgG in cooperation with CellTrend
GmbH (Germany) with a commercially available solid-
phase assay (One Lambda, Inc., USA), as described previ-
ously [3].
Cultivation and treatment of cells
Human microvascular endothelial cells-1 (HMEC-1s)
were serum-starved before all experiments in endothelial
cell medium with IgG-free fetal calf serum (FCS) 0.5%,
penicillin, 100 U/ml; streptomycin, 100 μg/ml, hydrocor-
tisone, 25 μM, epidermal growth factor 0.01 μg/ml, and
L-glutamine, 10 mM. Cells were incubated in a humidi-
fied atmosphere at 5% CO2 and 37°C. Human fibroblasts
were isolated from healthy donor skin. Dermis was re-
moved by dispase (4 mg/ml), and epidermis was digested
with collagenase type 1A (1 mg/ml). Fibroblasts were
cultivated in DMEM with IgG-free FCS, 10%, penicillin,
100 U/ml, streptomycin, 100 μg/ml, and amphotericin B,
2.5 μg/ml. For all experiments, passages three to eight
were serum-starved before experiments in DMEM with
IgG-free FCS 1%, penicillin 100 U/ml, streptomycin
Table 1 Patient and healthy donor characteristics
Parameter SSc patients (n = 33) Healthy donors (n = 13)
Mean age, years (SD) 55 (13) 43 (7)
Females/males, n (%) 24/9 (73/27) 9/4 (69/31)
Mean anti-AT1R Abs, units (SD) 16 (8) 9 (4)
Mean anti-ETAR Abs, units (SD) 15 (10) 6 (4)
Diffuse cutaneous form, limited cutaneous form, other, n (%) 21 (64), 10 (30), 2 (6) n.a.
Scl 70 positive, n (%), n.d. n (%) 13 (39), 3 (90) n.a.
Anti-centromere positive, n (%), n.d. n (%) 4 (12), 4 (12) n.a.
Duration since Raynaud phenomenon, years (±SD) 10 (11) n.a.
Duration since skin-involvement onset, years (±SD) 9 (7) n.a.
Duration since internal organ onset, years (±SD) 8 (7) n.a.
mRSS median (IQR) 8 (4-18) n.a.
Pulmonary arterial hypertension, n (%)a 14 (42) n.a.
Lung fibrosis, n (%)b 18 (55) n.a.
Mean DLCO% (SD) 50 (20) n.a.
Mean FVC% (SD) 85 (18) n.a.
Animal experiments SSc patients (n = 14) Healthy donors (n = 15)
Mean age, years (SD) 57 (14) 47 (8)
Females/males, n (%) 11/3 (79/21) 12/3 (80/20)
Mean anti-AT1R Abs, units (SD) 18 (10) 6 (4)
Mean anti-ETAR Abs, units (SD) 17 (10) 4 (3)
Diffuse cutaneous form, limited cutaneous form, other, n (%) 10 (71), 3 (21), 0 (0) n.a.
Scl 70 positive, n (%), n.d. n (%) 10 (71), 1 (7) n.a.
Anti-centromere positive, n (%), n.d. n (%) 2 (14), 3 (21) n.a.
Duration since Raynaud phenomenon, years (±SD) 11 (8) n.a.
Duration since skin-involvement onset, years (±SD) 10 (7) n.a.
Duration since internal-organ onset, years (±SD) 10 (9) n.a.
mRSS median (IQR) 8.5 (5.3-11) n.a.
Pulmonary arterial hypertension, n (%)a 8 (57) n.a.
Lung fibrosis, n (%)b 8 (57) n.a.
Mean DLCO% (SD) 42 (18) n.a.
Mean FVC% (SD) 77 (19) n.a.
n.d., not defined; n.a., not applicable.
aBy >35 mm Hg sPAP in echocardiography and/or 25 mm Hg mPAP in right-heart catheterization.
bBy HR-CT or x-ray.
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dothelial migration, neutrophils were freshly isolated
from healthy donor blood, as described [19]. Isolated
neutrophils were added to phosphate-buffered saline
(PBS)/IgG-free FCS 10%, and their migration capacity
was assessed with transwell culture inserts, as de-
scribed later. All reagents were purchased from PAA
Laboratories (Germany) and Invitrogen (Europe). For
all experiments that included receptor antagonism, in-
hibitors were added to cell cultures 18 and 3 hours
before IgG treatment. The most effective antagonist
concentration was determined in serial experiments.For individual receptor antagonism, AT1R was inhibited
by valsartan, and the ETAR by the selective inhibitor sitax-
entan. In parallel, the ETAR was inhibited by the dual
antagonist bosentan. All antagonists were used at 10–5 M
concentration, as described earlier [16,20]. Antagonists
were also applied simultaneously by combination of val-
sartan and sitaxentan (each at 10–7 M), or valsartan and
bosentan (at 10–5 M and 5 × 10–7 M, respectively). For in-
activation of NF-κB, tosyl-L-phenylalanine chlormethyl
ketone (TPCK) was used (3 × 10–6 M) 30 minutes before
IgG treatment. All antagonists tested nontoxic, indivi-
dually or simultaneously, in a cell-viability test (WST-8;
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formed for IL-8 protein expression, as described later
(range of 0.125 mg/ml to 1.5 mg/ml IgG). An IgG concen-
tration of 1 mg/ml was used in all experiments described.
Of note, a similar IgG concentration was used previously
[21]. Angiotensin II (Ang II) and endothelin-1 (ET-1) were
used at 10–6 M and 10–8 M concentrations, respectively,
and incubation times were the same as for IgG [16,20].
Scratch assay
For analysis of endothelial repair, uniform scratches were
made by 1-ml pipette tip in confluent HMEC-1 layers, as
described [22]. HMEC-1 cells were allowed to migrate into
scratch areas to close wounds for 24 hours in the presence
of SSc-IgG or NC-IgG. Cells were fixed in 96% ethanol,
stained with hematoxylin and eosin (Merck, Germany),
and light-microscopy pictures were taken (Leica DMIL
LED, LAS-EZ 2.0, Germany). Scratch areas were semi-
quantified with ImageJ software by measuring relative
scratch areas.
RNA, cDNA, and real-time PCR
RNA was isolated from HMEC-1 48 hours after IgG treat-
ment by NucleoSpin RNA II (Macherey-Nagel, Germany),
and cDNA was generated by M-MLV reverse transcriptase
(Promega, Germany), each according to manufacturer’s
instructions. Real-Time PCR reactions contained 5 μl of
cDNA, 0.25 mM dNTP (Bioline, Germany), 12 μg/ml bo-
vine serum albumin, 1 × SYBR Green-I (Molecular Probes,
Germany), 1 U Immolase (Bioline), 500 mM TRIS pH 8.8,
6 mM MgCl2, 0.5 nmol/ml primer mix (TIB MOLBIOL,
Germany), and were performed in MX3000P cycler
(Stratagene, Europe). Primers were designed by
Primer3 [23]. IL-8 forward 5′CAA-GAG-CCA-GGA-AGA-
AAC-CA3′, reverse 5′ACT-CCT-TGG-CAA-AAC-TGC-
AC3′. VCAM-1 forward 5′AAG-ATG-GTC-GTG-ATC-CTT-
GG3′, reverse 5′GGT-GCT-GCA-AGT-CAA-TGA-GA3′.
Eukaryotic translation elongation factor 1-α 1 (EEF1A1)
was used as housekeeping gene, forward 5′GTT-GAT-
ATG-GTT-CCT-GGC-AAG-C3′, reverse 5′GCC-AGC-
TCC-AGC-AGC-CTT-C3′. Samples were analyzed with
MxPro-Mx3005P (Stratagene), and expression levels
were normalized to the housekeeping gene.
Detection of IL-8 protein
HMEC-1 supernatants were collected 48 hours after IgG
treatment. IL-8 was measured with sandwich ELISA. The
coating antibody and the biotinylated detection antibody
were obtained as a matched-pairs kit from ImmunoTools
(Germany). Recombinant human IL-8 was obtained from
Biolegend (Germany) to generate a standard curve and
streptavidin conjugated HRP was obtained from Biolegend
(Germany). All reagents were used according to manufac-
turer’s instructions. Absorbance was measured at 450 nmby using the Emax microplate reader (Molecular Devices).
Data were analyzed by SoftMax Pro v5 (Molecular
Devices).
Transendothelial neutrophil migration and measurement
of neutrophil derived ROS
Supernatants from IgG-treated HMEC-1 (SSc-IgG or
NC-IgG, 48 hours) were placed in multiwell TM 24
plates followed by confluent HMEC-1 on transwell cul-
ture inserts (3 μM pore size, all Becton Dickinson).
Anti-IL-8 antibody (AB-208-NA; R&D Systems, Germany)
was added to supernatants (10 μg/ml) 30 minutes before
migration was assessed. Neutrophils were freshly isolated
from healthy donor blood, as described earlier and
added to inserts (2 × 106 cells/insert). Migrated cells were
counted automatically after 4 hours (CASY; Schärfe Sys-
tems, Germany). In parallel, neutrophils were isolated as
described earlier and were loaded with DCFH-DA (2′,7′-
dichlorofluorescin diacetate, 25 μM in PBS/IgG-free FCS
1%) in a humidified atmosphere at 5% CO2 and 37°C.
Loaded neutrophils were washed with 37°C warm PBS,
and 1 × 105 neutrophils were added to 200 μl of HMEC-1
supernatants treated with IgG in a 96-well round-bottom
cell-culture plate. After 30 minutes at 5% CO2 and 37°C,
cells were washed with PBS and fixed in 2% paraformalde-
hyde for 30 minutes at 4°C, washed again, and taken up in
150 μl PBS. Cells were transferred into a white 96-well
plate suitable for colorimetric analysis (F96 MicroWell;
Nunc, Germany), and generation of reactive oxygen spe-
cies (ROS) was analyzed at an excitation wavelength of
485 nm and at an emission wavelength of 538 nm by using
a fluorescence reader (Fluoroskan Ascent, Thermo Labsys-
tems, Germany).
Collagen detection
Confluent fibroblasts isolated from healthy donor skin
were grown on glass chamber slides (Iwaki, Japan) and
treated with SSc-IgG or NC-IgG for 5 days for maximum
collagen expression. Cells were fixed in paraformaldehyde
(2%) and triton X-100 (0.1%). Type I collagen immunocyto-
chemistry was performed by using a monoclonal primary
antibody reactive to human collagen protein 1A (sc-59772;
Santa Cruz, Santa Cruz, CA, USA) and a secondary
Cy3-conjugated antibody (C2181; Sigma-Aldrich). Nucleic
DNA was stained with 4′,6-diamidino-2-phenylindole
dihydrochloride (DAPI). Monochrome fluorescence pic-
tures were taken (Axioplan; Carl Zeiss MicroImaging
GmbH, Germany) at identical illumination times, and
fluorescence intensity signals were analyzed relative to cell
number by ImageJ software (NIH).
Antibody transfer into naïve mice
Female 7-week-old C57BL/6J mice (n = 7/group) were
maintained under specific pathogen-free conditions and
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SSc-IgG (800 μg, dissolved in 100 μl NaCl 0.9%) at day
0, as previously described for anti-AT1R Abs from pre-
eclampsia patients to study systemic events [24]. Pooled
IgG fractions were tested for anti-AT1R and anti-ETAR
Abs, as described earlier. NC-IgG fraction of low Ab
levels (anti-AT1R Abs units of 3.85 and anti-ETAR Abs
units of 2.5) and SSc-IgG fraction of high Ab levels
(anti-AT1R Abs units of 21.8 and anti-ETAR Abs units
of 17.91) were used for transfer. At day 7, mice were
killed, blood was harvested, and BALF of the right lung
was collected by using 2 × 650 μl PBS. Leukocytes were
counted and differentiated by means of microscopic ana-
lysis in a blinded fashion (800 cells counted/individu-
ally). KC plasma levels were quantified by Bio-Plex array
according to the manufacturer’s guide. For repeated IgG
treatment, female 8-week-old C57BL/6J mice (n = 7/
group) were maintained as described earlier. Mice were
treated with NC-IgG or SSc-IgG intravenously with
pooled IgG at day 1, day 17, day 30, and 7 days before
analysis, for a total of 100 days (200 μg, dissolved in 100
μl NaCl 0.9%). Histology analysis of the lungs was per-
formed by paraffin embedding, hematoxylin and eosin
(H&E) staining, and light microscopy (Axioplan 2; Carl
Zeiss MicroImaging GmbH).
Statistical analysis
Results were analyzed with GraphPad Prism software (ver-
sion 5.02) by using Mann-Whitney U test (NC-IgG
compared with SSc-IgG) and Wilcoxon signed-rank test
(SSc-IgG compared with SSc-IgG with blockers). Correl-
ation analyses were performed by nonparametric correl-
ation (Spearman) and linear-regression correlation. **P <
0.01 and *P < 0.05.
Results
Induction of IL-8 expression and release by
endothelial cells
Analysis of HMEC-1 activation by anti-AT1R and anti-
ETAR Abs-positive SSc-IgG showed a secretion of the
proinflammatory and profibrotic chemokine IL-8 into
culture supernatants. A dose-dependent pattern of IL-8
protein levels was found in HMEC-1 cells on stimulation
with 0.125 mg/ml to 1.5 mg/ml SSc-IgG, with the high-
est response between 0.5 and 1.5 mg/ml IgG (Figure 1A),
that was not present with NC-IgG. A comparison of
SSc-IgG versus NC-IgG treatment revealed increased IL-
8 levels with SSc-IgG treatment, with high variability in
individual IgG samples (P < 0.05; Figure 1B). Increased
IL-8 protein levels were reduced by individual as well as
simultaneous receptor antagonism (ETR-A and ATR-A/
ETR-A, each P < 0.05; Figure 1B). We further analyzed IL-
8 expression on an mRNA level and found a significant in-
crease in SSc-IgG- over NC-IgG-treated cells (P < 0.05;Figure 1C). Elevated IL-8 mRNA levels were reduced by
receptor antagonism, as indicated (ATR-A and AT1R-A/
ETR-A; P < 0.05 and P < 0.01, respectively, Figure 1C).
Similarly, significantly increased mRNA levels of VCAM-1
were induced by SSc-IgG treatment compared with NC-
IgG (P < 0.01; Figure 1D) and reduced by receptor an-
tagonism (ETR-A and ATR-A/ETR-A, each P < 0.05;
Figure 1D).
Induction of IL-8 and Ab-level-dependent neutrophil
transendothelial migration and ROS activation
Neutrophil recruitment and migration were analyzed by
transendothelial migration and ROS generation. Superna-
tants of SSc-IgG-treated HMEC-1 increased healthy donor
neutrophil migration through an endothelial cell layer com-
pared with supernatants of NC-IgG-treated HMEC-1 (P <
0.05; Figure 2A). Neutrophil migration toward supernatants
was significantly reduced by receptor inhibitors (ATR-A,
ETR-A, and ATR-A/ETR-A; all P < 0.05, Figure 2A).
Addition of an IL-8-neutralizing antibody to SSc-IgG
treated samples, as well as addition of NF-κB inactivator
TPCK, significantly decreased neutrophil transendothelial
migration (each P < 0.05, Figure 2B). Finally, SSc-IgG-
conditioned HMEC-1 supernatants significantly increased
generation of ROS in healthy donor neutrophils compared
with NC-IgG conditioned supernatants or untreated con-
trols (P < 0.05 and P < 0.01, respectively, Figure 2C). Statis-
tical analyses revealed a significant correlation between
neutrophil migration and anti-AT1R and anti-ETAR Ab
levels (r = 0.5849 and r = 0.7461, respectively, P < 0.05 and
P < 0.01, respectively, Figure 2D).
Influence on endothelial-repair function
As we observed endothelial cell activation and neutro-
phil recruitment, we also analyzed the influence of anti-
AT1R and anti-ETAR Abs on endothelial-repair function.
Artificially generated wounds in HMEC-1 layers were
analyzed in a scratch assay. Reduced cell-layer repair
was reflected by a larger wound area in HMEC-1 treated
with SSc-IgG compared with NC-IgG (P < 0.01, Figure 3A
and B). Individual and simultaneous receptor antagonism
improved endothelial repair of SSc-IgG-treated cells with
significant scratch-area reduction (ATR-A, ATR-A/ETR-
A; all P < 0.05, Figure 3B). Correlation analyses showed a
significant relation between impaired endothelial repair,
reflected by the wound area and anti-AT1R and anti-ETAR
Ab levels (r = 0.4111 and r = 0.4273, respectively; P < 0.05,
Figure 3C).
Induction of collagen expression in healthy donor-skin
fibroblasts
Because profibrotic events could be induced by anti-
AT1R and anti-ETAR Abs-positive SSc-IgG in HMEC-1
and neutrophil recruitment by IL-8, we additionally
Figure 1 Activation of HMEC-1 by anti-AT1R and anti-ETAR
Ab-positive SSc-IgG on protein and mRNA levels.
(A) Dose-dependent IL-8 secretion on different doses of anti-AT1R
and anti-ETAR Ab-positive SSc-IgG. Same treatment with NC-IgG
failed to demonstrate a dose-dependent IL-8 secretion pattern.
(B) Significant increase in IL-8 secretion with SSc-IgG versus NC-IgG
and decrease with receptor antagonism (NC-IgG, n = 9, SSc-IgG
n = 13, P < 0.05). (C) Increase in IL-8 mRNA levels by SSc-IgG versus
NC-IgG (NC-IgG, n = 7, SSc-IgG n = 18, P < 0.05). Receptor antagon-
ism leads to inhibition of IL-8 secretion, as indicated (SSc-IgG,
n = 13, P < 0.05, P < 0.01). (D) Increase in VCAM-1 mRNA levels with
SSc-IgG compared with NC-IgG (NC-IgG, n = 5, and SSc-IgG,
n = 6; P < 0.01) and inhibition by receptor antagonism as indicated
(P < 0.05). Mean and SEM, **P < 0.01, and *P < 0.05.
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collagen-expressing cells. Human fibroblasts were iso-
lated from healthy donor skin, and expression of type I
collagen was measured by immunocytochemistry on
treatment with anti-AT1R and anti-ETAR Abs-positive
SSc-IgG or NC-IgG. Increased type I collagen expression
was found with SSc-IgG treatment compared with NC-
IgG (Figure 4A). Measurement of collagen intensity rela-
tive to cell number showed significantly increased collagen
content in SSc-IgG treated cells over NC-IgG-treated cells
(P < 0.05, Figure 4B). Antagonism of ATR-A and ETR-A
resulted in a marked, not significant reduction of collagen,
due to high variability in the tested samples. Statistical
tests demonstrated a significant correlation between col-
lagen induction and anti-ETAR Ab levels, whereas only
a marked tendency was observed to anti-AT1R Ab
levels (r = 0.7619 and r = 0.6905, respectively; P < 0.05
and P = 0.0694, respectively, Figure 4C).
Induction of pulmonary neutrophil recruitment, increased
plasma levels of murine IL-8 analogue KC, and structural
alterations in lungs of naïve C57BL/6J mice
To analyze systemic effects of anti-AT1R and anti-ETAR
Abs in vivo, naïve C57BL/6J mice were subjected to pas-
sive transfer of pooled SSc-IgG or pooled NC-IgG, as
previously described [24]. Seven days after the transfer,
increased numbers of neutrophils were found in BALF
of SSc-IgG-treated mice as compared with NC-IgG-
treated mice (P < 0.01, Figure 5A), whereas no differ-
ences were observed for macrophages or lymphocytes.
Eosinophils were not detectable. Structural alteration of
the lungs were not observed by a single IgG-treatment.
However, plasma levels of the murine IL-8 analogue
KC were found to be increased after SSc-IgG treatment
compared with NC-IgG treatment (P = 0.05, Figure 5B).
Moreover, correlation analysis of KC plasma levels and
BALF neutrophil counts showed a strong positive correl-
ation (r2 = 0.6756 and P = 0.0019, Figure 5C). Repeated
IgG treatment resulted in profound structural alteration
of the lungs, including increased cellular density and
Figure 2 Neutrophil migration and ROS activation induced by anti-AT1R and anti-ETAR Ab-positive SSc-IgG. Supernatants of HMEC-1
conditioned with anti-AT1R and anti-ETAR Ab-positive SSc-IgG induce activation and recruitment of neutrophils, measured by transendothelial
migration and ROS generation. (A) Significantly increased transendothelial neutrophil migration with SSc-IgG-conditioned supernatants compared
with NC-IgG and decrease in samples with receptor antagonism, as indicated (NC-IgG, n = 5, SSc-IgG, n = 7, P < 0.05). (B) Neutrophil migration is
induced by IL-8 in supernatants shown by IL-8 neutralization (anti-IL-8 Ab) and NF-κB inactivation (TPCK) (SSc-IgG n = 7, P < 0.05). (C) Increased
ROS activation in neutrophils treated with SSc-IgG conditioned HMEC-1 supernatants compared with NC-IgG or untreated (NC-IgG, n = 8, SSc-IgG,
n = 12, P < 0.05; P < 0.01). Mean and SEM. **P < 0.01 and *P < 0.05. (D) Neutrophil migration shows a positive correlation to anti-AT1R Abs and
anti-ETAR Abs in the IgG samples used (NC-IgG, n = 5; SSc-IgG, n = 7; total, n =12). Spearman correlation.
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SSc-IgG compared with NC-IgG or untreated mice
(Figure 5D).
Discussion
The purpose of this study was to analyze the impact of
anti-AT1R and anti-ETAR Abs on the induction of vas-
cular inflammation and fibrosis, the key features of SSc.
The presence of elevated anti-AT1R and anti-ETAR Ab
levels in sera of SSc patients correlates with an increased
risk for the development of lung fibrosis, pulmonary ar-
terial hypertension (PAH), as well as with mortality, asdemonstrated previously [3]. Furthermore, these Abs in-
duced the expression of transforming growth factor-β
(TGF-β) in HMEC-1s, suggesting a potential involve-
ment in fibrosis [3]. Therefore, we sought to analyze the
actions of anti-AT1R and anti-ETAR Abs with a focus on
inflammation and fibrosis.
Here, we demonstrate that IgG samples from SSc pa-
tients positive for anti-AT1R and anti-ETAR Abs induce
proinflammatory and fibrotic events in endothelial cells and
healthy donor fibroblasts via angiotensin and endothelin-
receptor activation. Besides the activation of fibroblasts,
possible pathogenic effects mediated by SSc-IgG were
Figure 3 Diminished endothelial repair by treatment with anti-AT1R and anti-ETAR Ab-positive SSc-IgG. HMEC-1 treated with anti-AT1R
and anti-ETAR Ab-positive SSc-IgG reduce wound areas measured by a scratch assay. (A) Representative pictures of NC-IgG and of SSc-IgG-treated
cells and indicated inhibitors. (B) After 24 hours, wound areas are significantly greater in SSc-IgG versus NC-IgG treatment (NC-IgG, n = 6, SSc-IgG
n = 6, P < 0.01) and are significantly reduced by antagonists, as indicated (P < 0.05). Bar indicates 250 micron. Independent experiments were
performed at least twice. Mean and SEM, **P < 0.01 and *P < 0.05. (C) Wound area, as measurement of endothelial repair, shows a correlation to
levels of anti-AT1R Abs and anti-ETAR Abs (NC-IgG, n = 11; SSc-IgG, n = 14; total n = 25). Spearman correlation.
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increased neutrophil migration into target tissues.
Involvement of both the angiotensin and the endothe-
lin systems in SSc pathogenesis has been demonstrated
previously: Elevated serum levels of Ang II and ET-1 in
SSc patients were reported, as well as increased ET-1levels in SSc lung fibrotic tissue, indicating their central
role in SSc pathogenesis [15,25,26]. Also, a link between
angiotensin and endothelin-receptor activation and fi-
brosis, perhaps the most prominent feature of SSc, was
also suggested in the literature [26-28]. Activation of
AT1R by anti-AT1R Abs was reported previously for
Figure 4 Induction of collagen expression in fibroblasts by anti-AT1R and anti-ETAR Ab-positive SSc-IgG. Skin fibroblasts of healthy
donors increase expression of type I collagen with anti-AT1R and anti-ETAR Ab positive SSc-IgG. (A) Expression of type I collagen analyzed with
immunocytochemistry. Collagen expression is shown in green, and nucleic acid DAPI stain, in blue. Bar indicates 50 μm; shown are representative
pictures. (B) Significant increase in type I collagen with SSc-IgG versus NC-IgG (NC-IgG n = 4 and SSc-IgG n = 5, P < 0.05). Relative fluorescence
intensity was analyzed and normalized to cell number for each sample. Mean and SEM, *P < 0.05. (C) Collagen expression (type I collagen) shows
a significant correlation to anti-ETAR Ab levels and a trend to anti-AT1R Ab levels (NC-IgG, n = 3;, SSc-IgG, n = 5;, total n = 8; P < 0.05).
Spearman correlation.
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expression of extracellular matrix components (ECM), of
which collagen represents an important element, is a key
aspect in fibrosis development [12,14]. Angiotensin- and
endothelin-mediated collagen expression was demon-
strated [17,27]. Accordingly, we found increased expres-
sion of collagen in healthy donor dermal fibroblasts afterexposure to anti-AT1R and anti-ETAR Ab-positive SSc-
IgG. The intensity of collagen expression was signifi-
cantly dependent on levels of anti-ETAR Abs, showing
an Ab-dependent effect.
Besides the importance of fibrosis in SSc, many studies
propose that microvascular damage and inflammation
can precede fibrosis [4,30]. Additionally, autoimmune-
Figure 5 Systemic effects in naïve mice induced by anti-AT1R and anti-ETAR Ab-positive SSc-IgG. Anti-AT1R and anti-ETAR Ab-positive
SSc-IgG transfer increases neutrophil recruitment and KC levels (murine IL-8 analogue) in mice. (A) Significantly increased neutrophil counts
detected in BALF of mice treated with SSc-IgG compared with NC-IgG (n = 7; P < 0.01). (B) KC plasma levels in SSc-IgG-treated mice as compared
with NC-IgG-treated mice are increased by trend (NC-IgG, n = 5; SSc-IgG, n = 6; P = 0.05). (C) KC plasma levels significantly correlate with
neutrophil counts in BALF (NC-IgG n = 5, SSc-IgG, n = 6, r2 = 0.6756, P = 0.0019, linear regression correlation). Mean and SEM, **P < 0.01.
(D) Repeated treatment with IgG results in marked alterations of the lung structure of SSc-IgG-treated mice compared with NC-IgG or untreated
mice. Shown are representative light-microscopy pictures, H&E staining, ×12.5 magnification; bar indicates 500 μm. Asterisks indicate examples of
airway vessels; arrows indicate elevated cell density in interstitial tissue.
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strated to cause endothelial dysfunction [31], which can
lead to vessel leaks and lymphocyte infiltration [4,32]. In
this regard, anti-AT1R and anti-ETAR Abs induced micro-
vascular endothelial cell (HMEC-1) dysfunction after ex-
posure to positive SSc-IgG, resulting in reduced endothelial
repair in an Ab-level-dependent manner. Moreover, endo-
thelial dysfunction was further reflected by VCAM-1 ex-
pression on endothelial cells. Recently, the concept of
vascular leak was proposed to be a central feature of SSc
pathogenesis, highlighting the importance of changes in
the microvasculature in disease progression [33]. Our find-
ings indicate a general disturbance of endothelial functions
by SSc-IgG in vitro, which could probably also occur
in vivo. However, this hypothesis must be tested in more
detail in future experiments.
Furthermore, expression of the chemokine IL-8 with
proinflammatory and profibrotic properties has been re-
ported to be increased in sera, BALF, and fibroblasts in
SSc [7,8,10]. Accordingly, we found increased mRNA and
protein levels of IL-8 in HMEC-1 cells after exposure to
anti-AT1R and anti-ETAR Ab positive SSc-IgG. In line
with this, the murine IL-8 functional homolog KC was
found to be increased in plasma of naïve mice treated with
SSc-IgG. Given the chemotactic abilities of IL-8, wecongruously found increased neutrophil transendothelial
migration toward supernatants of SSc-IgG-activated endo-
thelial cells, which was dependent on IL-8. Increased neu-
trophil counts were also detected in vivo in BALF of naïve
mice treated with SSc-IgG, where neutrophil counts corre-
lated with KC plasma levels. In addition to signs of an
inflammatory fibrosis, repeated passive transfer of anti-
AT1R and anti-ETAR Ab-positive SSc-IgG resulted in
marked structural alterations of lungs with increased cel-
lular density in interstitial tissue. Our data suggest, fur-
thermore, that these Abs can also activate angiotensin and
endothelin receptors across both species because of high
receptor homology [34,35].
Our study has some limitations, of which the most
prominent is the use of total purified IgG instead of specif-
ically purified anti-AT1R and anti-ETAR Abs. Instead, we
here used receptor antagonists to demonstrate receptor-
mediated activation, as previously reported [21,29]. There-
fore, measured effects could partly result from other Abs,
suggested by incomplete effect inhibition by receptor an-
tagonists. Also, we cannot exclude the participation of
other Abs present in IgG on the measured effects. How-
ever, we have focused on effects that have already been
associated with angiotensin and endothelin-receptor acti-
vation. Another shortcoming is that the observed effects
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ples, indicating the very complex nature of these Abs.
Conclusions
In summary, our in vitro results indicate an induction of
proinflammatory and profibrotic events by anti-AT1R
and anti-ETAR Ab-positive SSc-IgG that might also be
present in vivo.
Our experimental data complement the association of
anti-AT1R and anti-ETAR Ab to clinical features of SSc,
especially with interstitial lung disease. On the basis of
these findings, we conclude that anti-AT1R and anti-
ETAR Abs can activate angiotensin and endothelin
receptor-expressing cells, among them some of the key
players of SSc pathogenesis, and thus affect mechanisms
of inflammation and fibrosis. Therefore, anti-AT1R and
anti-ETAR Abs may present a novel future target in SSc
therapeutic intervention.
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